The scan showed inflamed brain arteries. The decisive clue was microbial DNA.

A vascular pattern with an infectious undertow

The first major clue sat inside the arteries. Brain MRI showed small areas of acute ischaemia—tissue injured because its blood supply had been interrupted. Vessel imaging showed narrowing and enhancement of several large intracranial arteries, a pattern consistent with inflammation of the vessel walls. Cerebral vasculitis moved naturally towards the front of the differential.

Yet the cerebrospinal fluid, the fluid surrounding the brain and spinal cord, carried a second message. It contained excess lymphocytes, low glucose and raised protein. Common meningitis and encephalitis tests were initially negative, but the fluid still looked inflammatory. The question was no longer whether the nervous system was inflamed. It was what was driving the inflammation.

This account is paraphrased from a published case and deliberately omits names, location, exact dates and original images. It should not be read as a general rule for patients with stroke or vasculitis.

The clue that weakened the first explanation

A repeat scan changed quickly. One deep-brain lesion developed ring enhancement with central necrosis, meaning its edge took up contrast while the centre appeared damaged. New small infarcts appeared as well. That combination—progressive vessel injury, abnormal cerebrospinal fluid and an evolving necrotic lesion—left a purely autoimmune explanation less secure.

The report’s authors had sent broader infection tests while the familiar panels were negative. One was plasma microbial cell-free DNA testing, which looks for fragments of genetic material from many organisms in the bloodstream. It returned positive for Balamuthia mandrillaris. A targeted PCR test on cerebrospinal fluid, performed through the US Centers for Disease Control and Prevention, confirmed Balamuthia DNA.

The DNA result did not merely add a rare organism to a list. It connected the apparently separate findings: encephalitis, arterial-wall inflammation, small strokes and lesions that were changing across the brain.

What Balamuthia is—and why it hides

Balamuthia is a free-living amoeba, a single-celled organism found in soil, dust and water. The CDC says it may enter through broken skin or be inhaled with dust. In most patients the exact exposure is never established, so this case does not justify inventing one.

The organism can cause granulomatous amoebic encephalitis, often shortened to GAE. Granulomatous describes the organised inflammatory response that can form around the infection. Unlike the rapid warm-freshwater syndrome associated with Naegleria fowleri, Balamuthia illness can evolve over weeks or months and can affect healthy as well as immunocompromised people.

Its symptoms and scans are nonspecific. Headache, confusion, seizures, focal weakness and difficulty walking or speaking overlap with many neurological diseases. MRI may show one lesion or many, sometimes with ring enhancement, swelling, hydrocephalus or—in this published case—extensive vasculitis. The CDC notes that GAE can be mistaken for non-infectious conditions including stroke.

A diagnosis did not guarantee control

The published case was treated with a multidrug regimen assembled from the limited evidence available for survivors. Imaging and symptoms initially stabilised. The disease then progressed rapidly, with new ventricular, brainstem and cranial-nerve involvement, and the outcome was fatal.

That is the hardest part of the case. The diagnostic reveal is satisfying as a story, but the medicine did not become simple once the organism had a name. CDC guidance says effective treatment has not been established; recommendations rely on a small number of survivor reports, and nine out of ten people with GAE do not survive.

A separate CDC-published report describes survival after a regimen that included the repurposed drug nitroxoline. That is evidence that survival is possible, not proof of a standard curative treatment. The report itself describes the evidence base as inconsistent and derived from very small numbers.

The real diagnostic lesson

The lesson is not to add Balamuthia mechanically to every stroke or vasculitis work-up. This infection is exceptionally rare. The useful lesson is about discordance: when vascular imaging suggests inflammation but cerebrospinal fluid, lesion evolution or systemic testing does not fit the leading explanation, the category of the diagnosis may need reopening.

Here, vasculitis was real—it was visible in the vessel walls and associated with ischaemic injury. What changed was the cause. The inflammation was part of an infection rather than proof of a primary autoimmune disorder.

The case also shows what broader molecular testing can and cannot do. Unbiased sequencing can detect an organism that targeted panels were not designed to find, but results still require confirmation and clinical interpretation. One positive rare-pathogen signal should not replace pathology, targeted testing, multidisciplinary judgment or the authoritative local pathway.

For a learning record, save the source and the discriminating clue: mixed inflammatory cerebrospinal fluid plus rapidly evolving necrotic and vascular lesions. That is more useful than memorising the organism as a theatrical answer.